Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly

Nicholas C. Cullen, Antoine Leuzy, Shorena Janelidze, Sebastian Palmqvist, Anna L. Svenningsson, Erik Stomrud, Jeffrey L. Dage, Niklas Mattsson-Carlgren, Oskar Hansson
doi: https://doi.org/10.1101/2021.01.22.21250293

Article usage

Article usage: January 2021 to August 2025

AbstractFullPdf
Jan 202137216115
Feb 2021234769
Mar 20211182184
Apr 20211655173
May 20211294160
Jun 2021852831
Jul 2021441823
Aug 2021353125
Sep 2021512429
Oct 2021501131
Nov 202141924
Dec 2021261020
Jan 202230929
Feb 2022251821
Mar 2022201344
Apr 202226613
May 202216614
Jun 202226911
Jul 20222930
Aug 20222199
Sep 202235112
Oct 20222306
Nov 20222247
Dec 20221669
Jan 20231616
Feb 20231525
Mar 20231657
Apr 202328718
May 202315410
Jun 2023892
Jul 2023823
Aug 202319198
Sep 20231166
Oct 2023861
Nov 202319141
Dec 2023812
Jan 20241535
Feb 20241232
Mar 20241294
Apr 20248214
May 20241038
Jun 20241657
Jul 20241445
Aug 2024925
Sep 20241998
Oct 2024181311
Nov 20241438
Dec 20241229
Jan 20251317
Feb 2025162710
Mar 2025183216
Apr 202514108
May 2025152311
Jun 2025252814
Jul 2025302522
Aug 2025443
Back to top
Posted January 22, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly
Nicholas C. Cullen, Antoine Leuzy, Shorena Janelidze, Sebastian Palmqvist, Anna L. Svenningsson, Erik Stomrud, Jeffrey L. Dage, Niklas Mattsson-Carlgren, Oskar Hansson
medRxiv 2021.01.22.21250293; doi: https://doi.org/10.1101/2021.01.22.21250293
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area